Industry Breathes Sigh Of Relief Over UK Batch Release Move
One of the key regulatory conundrums thrown up by Brexit has been addressed after the government decided to continue using a list of approved countries to waive drug import testing requirements.
You may also be interested in...
UK consumer healthcare industry association, PAGB welcomes the UK government's recent announcement that its policy of not requiring domestic batch testing or certification of medicines imported from the EU/European Economic Area is to be made permanent.
The UK government is consulting on a set of options for batch testing of imported medicines as it seeks to balance patient safety principles with the need to avoid overly burdensome import requirements.
Industry representatives told a House of Lords committee about continuing Brexit-related problems such as the extra work involved in checking compliance with the EU Falsified Medicines Directive and the drawbacks of a proposed “dual regulatory regime.”